THE ROYAL NATIONAL ORTHOPAEDIC HOSPITAL NATIONAL HEALTH SERVICE TRUST

Their core work

The Royal National Orthopaedic Hospital (RNOH) in Stanmore is the UK's leading specialist orthopaedic hospital, providing clinical expertise in bone, cartilage, and musculoskeletal conditions. In H2020, they contributed as a clinical partner in two distinctly different research streams: engineering 3D-printed biomaterial scaffolds for cartilage and bone repair in osteoarthritis patients (BAMOS), and running a clinical drug trial testing Saracatinib — a repurposed cancer drug — as a treatment for fibrodysplasia ossificans progressiva (FOP), one of the rarest and most severe genetic disorders known (STOPFOP). Their core value to research consortia is access to specialist patient populations, clinical trial infrastructure, and orthopaedic surgical expertise that academic or industry partners cannot replicate.

What they specialise in

How they've shifted over time

In their first H2020 engagement (BAMOS, from 2017), RNOH was embedded in a materials science and bioengineering consortium, focused on additive manufacturing, scaffolds, and tissue engineering — an engineering-led approach to common orthopaedic problems like osteoarthritis. By 2019, with STOPFOP, their focus shifted entirely to pharmacological clinical research for an ultra-rare disease, reflecting a move from engineering collaboration toward rare disease trial participation. This is a notable pivot: from working on high-prevalence conditions with engineered solutions to working on extremely low-prevalence conditions with drug repurposing — two very different research modes for the same clinical institution.

RNOH appears to be expanding its EU research footprint from engineering-adjacent biomaterials work toward rare disease pharmacological trials, suggesting growing clinical trial infrastructure and appetite for orphan disease research collaborations.

How they like to work

RNOH has participated exclusively as a consortium partner — never as coordinator — across both projects, which fits the pattern of a clinical institution brought in for its patient access and medical expertise rather than its project management capability. With 12 unique partners across 8 countries from just 2 projects, they operate in medium-to-large international consortia. This suggests they are routinely sought out as a specialist clinical node rather than a research generalist.

RNOH has worked with 12 unique partners across 8 countries — a notably broad network for an organization with only 2 projects, suggesting both consortia were large and internationally diverse. No repeated partner overlap is visible from this data, indicating exposure to a wide range of research communities rather than deep ties with a fixed group.

What sets them apart

RNOH is not a university or research institute — it is a functioning specialist hospital, which means it brings something most consortium partners cannot: real patients, clinical trial approval pathways, and hands-on surgical or medical expertise. Their dual track in H2020 — materials engineering and rare disease trials — shows unusual breadth for a single clinical institution. For any consortium targeting musculoskeletal disease, bone repair, or orthopaedic application, RNOH is one of the few UK partners that can carry a project from bench to clinical validation.

Highlights from their portfolio

• STOPFOP
  Largest funding received (EUR 189,418) and targets fibrodysplasia ossificans progressiva — one of the rarest diseases in the world, affecting roughly 1 in 2 million people — making this a high-impact rare disease trial with global patient relevance.
• BAMOS
  An MSCA-RISE mobility project combining additive manufacturing with osteochondral tissue engineering, showing RNOH's ability to participate in cross-disciplinary engineering-clinical research well outside a traditional hospital role.